What is the main business of Novazil Therapeutics?

The main business activity of Novazil Therapeutics focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on July 9, 2008.

Where is the headquarters located?

The headquarters is located at: Ogrodowa 2, 05-092 Kiełpin.

Who is on the management board?

The management board consists of: Magdalena Dubiel (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 200,000 (approx. $54,025).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2019 to December 31, 2019.

What revenue was generated?

The company reported a revenue of $351 in 2019, which is a decrease of 100.0% compared to 2018.

No, in 2019 the company was not profitable, reporting a net loss of $30,261.

What is the largest operating cost?

The largest operating cost category falls under employee remuneration. This category amounted to $16,839 in 2019, representing 58% of all operating expenses.

Novazil Therapeuticssp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2008-07-09

Share capital

200,000.00 PLN

Registered address

Ogrodowa 2/A, 05-092 Kiełpin, Poland

Website

novazil.pl

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2020 – the filing deadline has passed.

2020not filed
201928/05/2020
201824/06/2019

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2019.

Results vs industry

Revenue

This companyUSD 350.75MedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD -30.26kMedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 29.28kMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 723.88kMedianUSD 883.09kAverageUSD 31.39m

Industry

Trademarks

Novazil Therapeutics currently holds no active trademarks with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2008.

Mark	Number	Classes	Status	Protected until
novazil THERAPEUTICS	Z.344430	5	Not registered	–

Mark	Protected until
novazil THERAPEUTICS	–

Authorized Representatives

Magdalena Dubiel – President of the Management Board

Manner of representation

President of the Management Board – independently; Vice-President of the Management Board – independently; two members of the management board jointly or a member of the management board acting jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
Krzysztof Dubielage 46	31	$8,373.85	15.5%
Magdalena Dubielage 47	169	$45,651.00	84.5%

Magdalena Dubiel and Krzysztof Dubiel hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

No beneficial owners recorded for the company Novazil Therapeutics.

Bank accounts

Registered as a VAT taxpayer on 2008-08-05.

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
BiotonS.A.	$72,911,351.08	bioton.com
Celon PharmaS.A.	$52,550,739.16	celonpharma.com
VercoS.A.	$43,577,172.02	verco.com.pl
VipharmS.A.	$30,660,173.61	vipharm.pl
MedicofarmaS.A.	$8,530,473.72	medicofarma.pl
VitamaS.A.	$4,287,087.38	vitama.pl
Munar PharmaS.A.	$85,649.72	munar.pl
Sanford Biotechsp. z o.o.	$2,586.64	sanfordbiotech.com
Cefeasp. z o.o.	$294.66	cefea.pl
Auxilius PharmaS.A.	$0.83	auxiliuspharma.com